Clarus Therapeutics Holdings, Inc.

Clarus Therapeutics Holdings, Inc., listed under the ticker BLUW, is a special purpose acquisition company that pursued a target in the healthcare and pharmaceutical sector. The company filed an 8-K current report with the SEC on May 3, 2021, reflecting material developments in its deal process. BLUW IPO'd in 2020 as part of the wave of healthcare-focused blank check vehicles that came to market during that period. The SPAC ultimately targeted Clarus Therapeutics, a specialty pharmaceutical company known for its oral testosterone replacement therapy product, representing a clinical-stage pharmaceutical combination. To access the full filing history, sponsor details, and deal timeline for BLUW, sign up for complete data at SpacDesk.